From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Human
Target Beta-amyloid (Aβ40/42)
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
CAS Number
  • none
Chemical and physical data
Formula C6496H10072N1740O2024S42
Molar mass 146.3 kg/mol (peptide)
 NYesY (what is this?)  (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.[4]

One clinical study was stopped on December 19, 2014 after disappointing results.[5]

As of late 2014, Phase III clinical trials are ongoing.[6]


  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
  2. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  3. ^ Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at
  4. ^
  5. ^
  6. ^ H. Spreitzer (10 November 2014). "Neue Wirkstoffe – Gantenerumab". Österreichische Apothekerzeitung (in German) (23/2014): 55.